- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02001649
Genetic Variants Associated With Adolescent Suicide Attempts (VGTSA)
Genetic Variants Associated With Adolescent Suicide Attempts: a Candidate-gene Association Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In France, suicide is the second leading cause of death among the 14-22 years population. Suicide behavior (SB) spans a spectrum ranging from suicidal ideation to suicide attempts and completed suicide. Several factors likely determine the predisposition to SB, including biological factors and psychosocial stressors. For biological factors, convergent evidence from adoption, family, and twin studies of suicide strongly suggests genetic contributions to liability for SB. Although genetic factors play a role in SB, identifying specific genes involved has proved challenging. Molecular-genetic technologies have made great advances in the past decade, including genome- wide searches for disease-causing genes with the linkage disequilibrium (LD) approach. Despite being a major public health problem in the youth population, genetic associations studies regarding suicidal behavior in adolescence are still rare. Genes that code for proteins involved in regulating serotonergic neurotransmission have thus been major candidate genes for association studies of SB. Among them, genes for serotonin metabolism (tryptophan hydroxylase, TPH), serotonin transport (5-HTT), and the serotonergic 2A (5-HT2A) receptor have received the most research attention.
The identification of relevant genetic variants or SNPs in others genes which are involved in the neurobiological pathways (which the alteration may contribute to a suicidal behavior) can help not only to advance knowledge of the genetic bases of suicide but also to identify new therapeutic targets.
On the basis of review of the literature, investigators will identify candidate genes that have been reported to be associated with suicidal events.
The investigators will target genes related to central serotonergic and noradrenergic neurotransmission, and monoamine metabolism (MAOA). The investigators will also study genes involved in glutamatergic neurotransmission (GRIK2, GRIA3) and in the HPA axis (FKBP5) and genes that code for neurotrophic proteins (BDNF).
DNA will be obtained from saliva. All genotyping will be carried out using standard polymerase chain reaction-based techniques that are routinely used in the Human Genetics Laboratory. DNA segments containing the target variable site will be amplified using unique sequence flanking primers.
Tests of association between genetic variant and suicide attempt will be conducted using Chi squared and Armitage Trend Tests. Logistical regression analyses will be performed to evaluate the contribution of individual genetic variant to the prediction of suicide attempt, and to examine SNPs for potential gene-gene and gene-environment interactions.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Haute Normandie
-
Rouen, Haute Normandie, France, 76000
- CHU Rouen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Case :
- Age at admission between 13 and 17 years old
- Hospitalized for attempted suicide
- Absence of prominent mental retardation or organic brain damage
- Fluent in French
- Able to comprehend the study procedures and to undergo entry assessments safely
- Provided written informed consent for study participation, and additional consent from the patient's parents or guardians
- Northern and Western European ancestry (HapMap-CEU)
- Medical insurance coverage
Control :
- Healthy adult volunteers
- No present or past psychiatric illness
- No personal history of suicidal behavior and without a family history of suicide
- Provided written informed consent for study participation
- Northern or Western European ancestry (HapMap-CEU)
- Medical insurance coverage
Exclusion Criteria:
Case:
- Inability to get an informed and valid consent
- Home address outside the selected hospitals' geographic areas
- Intellectual disability or organic brain damage
- Origine ethnique non CEU
- Absence of medical insurance coverage
- Pregnant or lactating women
- Without Northern or Western European ancestry (HapMap-CEU)
Control :
- Inability to get an informed and valid consent
- Intellectual disability or organic brain damage
- History of suicidal behavior
- Psychiatric disorder, past or present
- Family history of suicide
- Borderline personality disorder
- Absence of medical insurance coverage
- Pregnant or lactating women
- Without Northern or Western European ancestry (HapMap-CEU)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Inpatient group SNP Genotyping
Patients will be recruited from pediatric departments in which 13 -17 y old adolescents are hospitalized for a suicide attempt. Data will be collected through self-administered questionnaires and face to face interview. DNA will be extracted from saliva sample. Individuals will be genotyped at a total of 96 SNPs |
Individuals were genotyped at a total 96 SNP from 15 candidate gene
|
Other: Control group SNP Genotyping
Control subjects are young adults without suicide attempt and without mental disorders
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Odds ratio (OR) and 95% confidence interval (CI) will be estimated using a logistic regression model to assessing the contribution of each polymorphism as a risk factor in predicting suicidal behavior
Time Frame: Between day 1 and day 5 during hospitalization
|
Measure is a composite outcome measure consisting of multiple measures Post hoc Bonferroni correction will be employed to correct for multiple testing. Chi- square test will performed to analyze genetic associations |
Between day 1 and day 5 during hospitalization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: BOJAN MIRKOVIC, MD, CHU Rouen, Fédération de pédopsychiatrie du Pr Gérardin
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013/092/HP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attempt Suicide
-
Centre Hospitalier Universitaire de NīmesRecruitingSuicidal Ideation | Suicide, AttemptFrance
-
Nantes University HospitalUniversity Hospital, Angers; Poitiers University Hospital; Saint Antoine University... and other collaboratorsUnknownSuicide Attempt by ScaldingFrance
-
University Hospital, MontpellierINSERM U960 - Cognitive Neuroscience Laboratory - Paris, FranceTerminatedDepression | History of Suicide AttemptFrance
-
Assistance Publique - Hôpitaux de ParisRecruitingSerious Suicide AttemptFrance
-
University Hospital, BrestTechnopôle Brest-Iroise: LANESTEL SARL, 38 rue Jim Sevellec, 29200 BrestUnknownPatients Having Realized a Suicide AttemptFrance
-
Hôpital le VinatierRecruiting
-
Japan Foundation for Neuroscience and Mental HealthNational Center of Neurology and Psychiatry, JapanCompleted
-
Eli Lilly and CompanyCompleted
-
Franciscan Hospital For Children, INC.National Institute of Mental Health (NIMH); Harvard UniversityRecruitingSuicidal Ideation | Self-Injurious Behavior | Suicide AttemptsUnited States
Clinical Trials on SNP Genotyping
-
Sinew Pharma Inc.TerminatedNASH - Nonalcoholic SteatohepatitisTaiwan
-
Kyungpook National University HospitalCompletedAge-Related Macular DegenerationKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer Center; Mayo Clinic; Dana-Farber Cancer Institute; Duke University and other collaboratorsActive, not recruitingLeukemiaUnited States
-
Mayo ClinicCompletedMyocardial Infarction | Obesity | Breast Cancer | Osteoarthritis | Atrial Fibrillation | Graves Disease | Lung Cancer | Celiac Disease | Prostate Cancer | Colon Cancer | Diabetes Type 2United States
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Asfendiyarov Kazakh National Medical UniversityCompletedLymphoma | B Cell LeukemiaKazakhstan
-
Sohag UniversityRecruiting
-
Sohag UniversityNot yet recruiting
-
Sohag UniversityRecruitingType 2 Diabetes MellitusEgypt